Displaying drugs 7126 - 7150 of 8033 in total
RPI-MN
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
Matched Description: … developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of …
Afamitresgene autoleucel
Afamitresgene autoleucel is a specific Peptide Enhanced Affinity Receptor T cell product comprised of autologous CD4 and CD8 positive T cells genetically engineered with an affinity-enhanced T cell receptor to target cancer-testis antigen MAGE-A4
Investigational
Matched Description: … Afamitresgene autoleucel is a specific Peptide Enhanced Affinity Receptor T cell product comprised of …
XL999
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of …
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
AV-COVID-19
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).
The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2...
Investigational
Matched Description: … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with ... As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252 …
COVID19 s-vax loaded autologous dendritic cell vaccine
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.
Dendritic Cells (DCs) are showing potential as natural adjuvants...
Investigational
Matched Description: … and immunogenicity of the vaccine. ... cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of ... As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety …
SARS-CoV-2 Sclamp
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in...
Investigational
Matched Description: … The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations ... Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and ... As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical …
Asimadoline
Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of...
Investigational
Matched Description: … Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt ... It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients …
ADL 10-0101
ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at...
Investigational
Matched Description: … of inflammatory pain, itch and visceral pain. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment …
Astaxanthin
Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may...
Investigational
Matched Description: … It is found in the majority of aquatic organisms with red pigment. ... Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. …
Benzylfentanyl
Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM...
Illicit
Matched Description: … Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America ... Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl …
WIN 55212-2
WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of...
Experimental
Matched Description: … is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of ... is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of …
Viral Macrophage-Inflammatory Protein
Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially...
Investigational
Matched Description: … The structure of vMIP consists of 71 residues and is a monomer under most conditions. …
Aminooxyacetic acid
A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of gamma-aminobutyric acid in tissues. [PubChem]
Experimental
Matched Description: … A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of …
Glycocholic acid
The glycine conjugate of cholic acid. It acts as a detergent to solubilize fats for absorption and is itself absorbed.
Experimental
Investigational
Matched Description: … The glycine conjugate of cholic acid. …
ALKS 29
ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Investigational
Matched Description: … ALKS 29 is a new product candidate for the treatment of alcohol dependence. …
LLL-3348
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Investigational
Matched Description: … The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable …
Conatumumab
Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
Investigational
Matched Description: … Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer …
Epacadostat
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
Investigational
Matched Description: … Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma …
Basimglurant
Basimglurant has been used in trials studying the diagnostic and treatment of Depression, Fragile X Syndrome, and Major Depressive Disorder.
Investigational
Matched Description: … Basimglurant has been used in trials studying the diagnostic and treatment of Depression, Fragile X Syndrome …
ZD-6126
ZD6126 has been used in trials studying the treatment of Kidney Neoplasms, Colorectal Neoplasms, Metastases, Neoplasm, and Carcinoma, Renal Cell.
Investigational
Matched Description: … ZD6126 has been used in trials studying the treatment of Kidney Neoplasms, Colorectal Neoplasms, Metastases …
AZD-1236
AZD1236 has been used in trials studying the basic science and treatment of Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Investigational
Matched Description: … AZD1236 has been used in trials studying the basic science and treatment of Cystic Fibrosis and Chronic …
TAK-448
TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
Investigational
Matched Description: … TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic …
Dinaciclib
Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others.
Investigational
Matched Description: … Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and …
Ganetespib
Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.
Investigational
Matched Description: … Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid …
Displaying drugs 7126 - 7150 of 8033 in total